May 2019

LeucoTox submitted patent application at the European Patent Office.


October 2020

Preclinical models show efficacy of LeucoTox in myeloid leukemia in vivo.


August 2020

LeucoTox performed first xenograft experiments with substantial treatment efficacy.


June 2021

LeucoTox has submitted a proposal for pre-seed funding at the BioM Biotech Cluster in Munich, Germany.